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Aim and Hypothesis: Despite the proven symptomatic and mortality benefit of cardiac
resynchronization therapy (CRT), there is anecdotal evidence it may be pro-arrhythmic
in some patients. We aimed to identify if there were significant differences in
the incidence of ventricular arrhythmias (VAs) in patients undergoing CRT-D and
implantable cardioverter-defibrillators (ICD) implantation for primary prevention indication.
We hypothesized that CRT is unlikely to be pro-arrhythmic based on the positive mortality
and morbidity data from large randomized trials.
Methods and Results: A retrospective analysis of device therapies for VA in a primary
prevention device cohort was performed. Patients with ischemic (IHD) and non-ischemic
(DCM) cardiomyopathy and ICD or CRT+ICD devices (CRT-D) implanted between 2005
and 2007 without prior history of sustained VA were included for analysis. VA episodes
were identified from stored electrograms and defined as sustained (VT/VF) if therapy
[anti-tachycardia pacing (ATP) or shocks] was delivered or non-sustained (NSVT) if not.
Of a total of 180 patients, 117 (68% male) were in the CRT-D group, 42% IHD, ejection
fraction (EF) 24.5 ± 8.2% and mean follow-up 23.9 ± 9.8 months. 63 patients (84%
male) were in the ICD group, 60% IHD, EF 27.7 ± 7.2% and mean follow-up 24.6 ±
10.8 months. Overall, there was no significant difference in the incidence of VA (35.0
vs. 38.1%, p = 0.74), sustained VT (21.3 vs. 28.5%, p = 0.36) or NSVT (12.8 vs. 9.5%,
p = 0.63) and no significant difference in type of therapy received for VT/VF: ATP (68 vs.
66.6%, p = 0.73) and shocks (32 vs. 33.3%, p = 0.71) between the CRT-D and ICD groups,
respectively.
Conclusion: In patients with cardiomyopathy receiving CRT-D and ICDs for primary
prophylaxis, there was no significant difference in the incidence of VA. From this single
center retrospective analysis, there is no evidence to support cardiac resynchronization
causing pro-arrhythmia.
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INTRODUCTION
Cardiac resynchronization therapy (CRT) is an established treat-
ment for chronic heart failure with proven mortality andmorbid-
ity benefits (Abraham et al., 2002; Cohen and Klein, 2002; John
Sutton et al., 2003). In patients with heart failure and left bundle
branch block on surface ECG, CRT reduces symptoms, hospital-
ization and sudden death (Cazeau et al., 2001; Abraham et al.,
2002; Higgins et al., 2003). Patients with congestive heart failure
are at increased risk of developing both monomorphic ventricu-
lar tachycardia (VT) (Figure 1) and ventricular fibrillation (VF)
(Stevenson and Stevenson, 2001). Re-entry within the left ventri-
cle (LV) is responsible for the majority of VT circuits (Stevenson
and Delacretaz, 2000). In selected patients, implantable car-
dioverter defibrillator (ICD) implantation, singly or in combina-
tion with CRT (CRT-D), is indicated for primary or secondary
prevention purposes, with proven mortality benefit and reduced
risk of arrhythmic death for both device type (Walker et al., 2000;
Zagrodzky et al., 2001; Martinelli et al., 2002; Higgins et al., 2003;
Bristow et al., 2004; Cleland et al., 2005; Voigt et al., 2006). Based
on the available data we hypothesized that CRT is unlikely to be
pro-arrhythmic. However, there have also been numerous reports
of pro-arrhythmia in patients treated with CRT, questioning its
safety (Medina-Ravell et al., 2003; Di Cori et al., 2005; Fish et al.,
2005; Shukla et al., 2005; Germano et al., 2006; Spragg and Kass,
2006). Various mechanisms for this phenomenon have been pos-
tulated, including reversal of the normal transmural sequence of
activation, QT prolongation and increasing transmural disper-
sion of repolarization but much of these data are derived from
in-vitro studies (Fish et al., 2005) and there has been a lack
of clinical studies designed to investigate this problem in more
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FIGURE 1 | A device interrogation printout showing ventricular tachycardia.
detail. Given the conflicting evidence for the pro-arrhythmic
effects of CRT and the lack of clinical data, the aim of the present
study was to investigate and compare the incidence of ventricu-
lar arrhythmias (VAs) in patients with either CRT/CRT-D or ICD
devices indicated for primary prevention implanted in our center.
METHODS
This study is a single center retrospective analysis of patients
with ICD and CRT/CRT-D devices implanted between January
2005 and December 2007. All patients had ischemic or non-
ischemic cardiomyopathy (idiopathic dilated cardiomyopathy)
and poor left ventricular function. Patients with hypertrophic car-
diomyopathy, infiltrative cardiomyopathy, ion-channelopathies,
and congenital heart disease were excluded from the study. A
total of 840 patients’ device implantation records and indica-
tions were analyzed. Patients with devices implanted for sec-
ondary prevention of VA and those with a separate bradycardia
pacing indication were excluded. Patients with normal left ven-
tricular ejection fraction (EF) were excluded from the study.
Demographic and clinical data, including renal function, were
identified from patient records. Baseline renal function was clas-
sified using the estimated glomerular filtration rate (eGFR) by
Modification of Diet in Renal Disease (MDRD) formula (Levey
et al., 1999). Patients with eGFR< 60mls/min/1.73 m2 were clas-
sified as having chronic kidney disease (CKD) stage 3 or worse
(National Kidney Foundation, 2002).
The cohort was divided into an ICD group and a CRT-D
group. After exclusions, a total of 180 patients’ device records were
included. Details of episodes of VAs were obtained from patient
notes, device clinic records and analysis of stored electrograms,
downloaded device data from the previous 2.5 years, if available,
in all patients.
DEFINITIONS
Device therapy was classified into either anti-tachycardia pacing
(ATP) or shocks. Patients who received a combination of ATP
and shocks for a single arrhythmia episode were classified in the
“shock” category. VAs were defined as a VT or VF episode meet-
ing device detection criteria, which then led to therapy delivery.
Non-sustained ventricular tachycardia (NSVT) was defined as a
VA episode detected by the device without therapy delivery due
to spontaneous termination. Therapies delivered due to atrial
fibrillation (AF) or supraventricular tachycardia were deemed
inappropriate and were not included for analysis.
Patients had devices from the following manufacturers:
Medtronic, Boston Scientific, St Jude and Biotronik. Criteria for
detection of VAs were programmed to nominal settings at implant
and were altered only at their physician’s discretion. This also
applied to therapy programming.
STATISTICS
Categorical variables are presented as percentages and continu-
ous variables as mean ± SD and/or median (interquartile range)
where appropriate. Categorical variables were compared by the
X2-test or Fisher’s exact test where applicable. Kaplan-Meier anal-
ysis was performed for survival probability and log rank test
was used for time to event comparison. A P-value < 0.05 was
considered significant. Statistical comparisons were done using
statistical software SPSS 15 (Manufacturer name, city, USA).
RESULTS
PATIENT CHARACTERISTICS
Between 2005 and 2007, 63 patients in the ICD group and
117 patients in the CRT-D group were identified after exclu-
sion criteria. Mean follow-up was 24.6 ± 10.8 months in the
ICD group and 23.9 ± 9.8 in the CRT-D group. Baseline patient
characteristics are shown in Table 1.
Patients in the CRT-D group had standard indications, includ-
ing LVEF ≤35%, NYHA class III-IV symptoms and QRS dura-
tion >150ms or QRS >120ms and echocardiographic evidence
of dyssynchrony. All patients were on the maximum tolerated
heart failure therapy. Of the 117 patients in the CRT-D group,
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Table 1 | Patient characteristics of both groups (ACE, Angiotension
Converting Enzyme; ARB, Angiotensin Receptor Blockers; CKD,
Chronic Kidney Disease; NYHA, New York Heart Association).
Patient CRT-D group ICD group Significance
characteristics (n = 117) (n = 63)
Age 66 ± 11 65.3 ± 13 > 0.05
Gender
Male 80 (68%) 53 (84%) 0.02
Female 37 (32%) 10 (16%)
Etiology
Ischemic cardiomyopathy 49 (42%) 38 (60%) 0.03
Non-ischemic ardiomyopathy 68 (58%) 25 (40%) > 0.05
Ejection fraction (%) 24.5 ± 8.2 27.7 ± 7.2 > 0.05
Follow-up (months) 23.9 ± 9.8 24.6 ± 10.8 > 0.05
NYHA class (median) III II 0.0003
ACE inhibitors or ARBs 97% 92% > 0.05
Amiodarone 14% 25% > 0.05
Beta blockers 86% 69% 0.026
CKD stage 3 or above 46% 36% > 0.05
80 (68%) were male, mean age 66 ± 11 years and of the 63
patients in the ICD group 53 (84%) were male, with a mean age
of 65.3 ± 13 years. The etiology of the underlying LV dysfunc-
tion in the CRT-D group was ischemic in 49 (42%) patients and
non-ischemic cardiomyopathy in 68 (58%) patients. In the ICD
group, 38 (60%) patients had ischemic cardiomyopathy. Mean
LV EF was 24.5 ± 8.2% in the CRT-D group and 27.7 ± 7.2%
in the ICD group. Mean follow-up was 23.9 ± 9.8 months and
24.6 ± 10.8 months in the CRT-D and ICD groups, respectively.
The median NYHA class of patients in the CRT-D group was 3
and was class 2 in the ICD group. 97% of patients were estab-
lished on an ACE inhibitor or Angiotensin receptor blocker in
the CRT-D group and 92% in the ICD group. 14% in the CRT-
D group were on Amiodarone and 25% in the ICD group. In
the CRT-D group 86% were on a beta-blocker and 69% in the
ICD group. Analysis of patients’ renal function revealed 46% of
patients had CKD stage 3 or above in the CRT-D group and 36%
of patients in the ICD group. Both groups were well matched for
age, etiology, EF, follow up duration, ACE inhibitor/ARB use and
the presence of CKD Stage 3 or more (all p = NS) (see Table 1).
Disparity was seen between the groups for NYHA class (worse in
CRT-D group), gender (more females CRT-D group), number of
patients with ischemic cardiomyopathy (less ischemic cardiomy-
opathy in CRT-D group) and beta-blocker usage (higher use in
CRT-D group).
INCIDENCE OF VENTRICULAR ARRHYTHMIAS
In the CRT-D group, 35% of patients (41/117) exhibited VAs,
and of these, 25 (60.9%) were VT and 16 (39.02%) were NSVT.
Among those patients with VT, 17 (68%) were treated with ATP
and 6 (24%) with shocks, 2 (8%) were treated with ATP followed
by a shock. In the ICD group 24/63 (38.1%) patients had VAs,
of which18 (75%) were VT and 6 (25%) were NSVT. Among
the patients who had VT, 12 (66.6%) were treated with ATP
and 6 (33.3%) with shocks. There was no significant difference
FIGURE 2 | Incidence of tachy-arrhythmias in the CRT-D and ICD
groups.
in the incidence of VAs between the CRT-D and ICD groups
(p = 0.74). There were no significant differences in the incidence
of VT (p = 0.36) and NSVT (p = 0.63), nor was there a signif-
icant difference in the number of patients who received ATP or
shocks (p = 0.714) in either groups (Figure 2).
Using a Kaplan-Meier survival analysis, no significant dif-
ference in event free survival probability between the two
groups were identified for freedom from VA, VT/VF or NSVT
(Figures 3–5).
A Cox regression analysis was performed using Backward
stepwiseWard rule for the occurrence of VT/VF with covariates—
Age, Sex, type of intervention (ICD or CRT-D), Use of
Amiodarone, Beta blocker, ACE inhibitor, NYHA Class and mean
EF at the time of device implant and CKD. This showed that
Male Sex (p = 0.001), presence of CKD (eGFR < 60) (p = 0.01)
and Age (p = 0.012) to be significant predictors for Time to
VT/VF.
SUB-GROUP ANALYSIS BASED ON ETIOLOGY
A further sub-group analysis was performed according to etiology
of left ventricular dysfunction.
Ischemic cardiomyopathy sub-group
Baseline characteristics were similar between both groups
(Table 2), except NYHA class (p = 0.0003) and numbers of
patients on Amiodarone (p = 0.02) or Beta-blockers (p = 0.03).
VAs occurred in 21/49 (42%) in the CRT-D group vs. 16/38 (42%)
in the ICD group (p = 0.94). VT/VF occurred in 14/49 (28.5%)
patients in the CRT-D group vs. 11/38 (28.9%) in the ICD group
(p = 0.96) (Figure 6).
Non-ischemic cardiomyopathy sub-group
There were more males in the ICD group (88%) than the CRT-
D group (55%) (p = 0.002) (Table 3). VAs occurred in 20/68
(29%) patients in the CRT-D group vs. 9/26 (35%) in the
ICD group (p = 0.62). Sustained VA (VT/VF) occurred in 11/68
(16%) patients in the CRT-D group vs. 8/26 (31%) in the ICD
group (p = 0.15), implying a trend toward a higher incidence
of sustained VA in patients with ICDs although statistically not
significant (Figure 7).
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FIGURE 3 | Kaplan Meyer survival analysis of the occurrence of
ventricular tachyarrhythmia between ICD and CRT-D group.
FIGURE 4 | Kaplan Meyer survival analysis of the occurrence of NSVT
between ICD and CRT-D groups.
After stratifying into Ischemic and Non Ischemic
Cardiomyopathy, a Cox regression analysis was performed
using Backward stepwise Ward rule for the occurrence of VT/VF
with covariates—Age, Sex, type of intervention (ICD or CRT-D),
Use of Amiodarone, Beta blocker, ACE inhibitor, NYHA Class
and mean EF at the time of device implant and presence of CKD.
Age (p = 0.08) and Male sex (p = 0.027) were found to
be independent predictor for time to VT/VF in Ischemic
Cardiomyopathy group. In the NICM group, Age (p = 0.01), Sex
(p = 0.04), Presence of CKD (p = 0.01) and Intervention type-
ICD (p = 0.03) were independent predictors of time to VT/VF
occurrence.
DISCUSSION
The principal finding of the present study was the observation of
no difference in burden of VA in patients implanted with ICDs
or CRT-Ds for primary prevention purposes, in a reasonably
FIGURE 5 | Kaplan Meyer survival analysis of the occurrence of VT/VF
between ICD and CRT-D groups.
well matched cohort. To our knowledge, this is the first retro-
spective study designed to specifically examine the difference in
incidence of any VAs between these patient groups. In addition,
there were no significant difference in the occurrence of sus-
tained VA in the two groups (21.3% in CRT-D group vs. 28.5% in
ICD group, p = 0.36). Sub-group analysis showed similar reduc-
tions in VAs in different etiologies of underlying cardiomyopathy.
These results are supported by data from the COMPANION trial
(Comparison of Medical Therapy, Pacing, and Defibrillation in
Chronic Heart Failure study) (Bristow et al., 2004), which showed
a significant reduction in all cause mortality and hospitalizations
in patients receiving CRT or CRT-D devices compared to opti-
mal medical therapy alone. The latter is important as one would
assume an increase in sustained VAs would have led to ICD thera-
pies resulting in increased hospitalizations in these patients. This
is corroborated by data from the Cardiac Resynchronization in
Heart Failure study (CARE-HF) of patients receiving CRT com-
pared to medical therapy (Cleland et al., 2005), which showed
a 37% reduction in all cause mortality and hospitalizations,
but also significant improvement in patients’ quality of life at
90 day follow-up. This too implies a reduction in ventricular
tachyarrhythmia burden.
MECHANISMS BY WHICH CRT MAY BE PRO- OR ANTI-ARRHYTHMIC
It is well known that CRT may cause reverse mechanical and
electrical remodeling of the LV (Saxon et al., 2002; Auricchio
and Abraham, 2004; Leclercq and Hare, 2004). At a sub-cellular
level, the favorable role of CRT in re-organization of sub-cellular
structure and protein distribution associated with excitation con-
traction (EC) coupling has been shown by Sachse et al. (2012)
The role of sub-cellular structure transverse tubular system (t-
system) along with spatial orientation of Ryanodine receptor
clusters is an important requisite in EC coupling, which is invari-
ably altered in dyssynchronous heart failure (Louch et al., 2010).
CRT has been shown to restore structure and functional restitu-
tion of the t-system as early as 3 weeks in canine model (Sachse
et al., 2012). The role of miRNA down regulation in heart failure
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Table 2 | Ischemic cardiomyopathy—Patient characteristics.
Patient CRT-D group ICD group Significance
characteristics (n = 49) (n = 38)
Age 67.5 ± 9 71.4 ± 9 0.60
Gender
Male 42 (85%) 31 (81%) 0.77
Ejection fraction (%) 26.08 ± 7.7 27.0 ± 6.3 0.56
Follow-up (months) 24.24 ± 10.4 24.79 ± 11.1 0.81
NYHA class (median) III II 0.0003
ACE inhibitors or ARBs 96% (36) 95% (30) 0.96
Amiodarone 13% (5) 37% (12) 0.02
Beta blockers 60% (23) 84% (27) 0.03
CKD stage 3 or more 59% (29) 46% (17) 0.27
FIGURE 6 | Kaplan Meyer survival analysis of the occurrence of VT/VF
between ICD and CRT-D groups in the ischemic cardiomyopathy
patient cohort.
Table 3 | Non-ischemic cardiomyopathy—Patient characteristics.
Patient CRT-D group ICD group Significance
characteristics (n = 68) (n = 26)
Age 63.6 ± 13 61.3 ± 14 0.46
Gender
Male 55% (38) 88% (23) 0.002
Ejection fraction (%) 23.4 ± 8.5 28.6 ± 9.0 0.011
Follow-up (months) 23.7 ± 9.5 23.8 ± 10.7 0.9
NYHA class (median) III II 0.0003
ACE inhibitors or ARBs 75% (51) 80% (21) 0.18
Amiodarone 12% (8) 4% (1) 0.43
Beta blockers 75% (41) 90% (19) 0.2
CKD stage 3 or more 36% (25) 23% (6) 0.22
patients and CRT and miRNA response to CRT in both respon-
ders and non-responders to CRT have been recently shown by
Sardu et al. focusing on the miR-mediated modulation of cardiac
angiogenesis, apoptosis, fibrosis and membrane ionic currents
(Sardu et al., 2014). Possiblemechanisms for reduction in VAwith
CRT include a decrease in local conduction delay, decreased pause
FIGURE 7 | Kaplan Meyer survival analysis of the occurrence of VT/VF
between ICD and CRT-D groups in the Non-Ischemic Cardiomyopathy
patient cohort.
dependant ectopic firing and decreased circulating catecholamine
levels through hemodynamic effects (Zagrodzky et al., 2001).
Over time, electrical and mechanical remodeling of the ventri-
cles might exert anti-arrhythmic effects. In theMADIT-CRT trial,
“super-responders” to CRT-D (with reductions of >25% in left
ventricular end-systolic volume) had significantly lower VA com-
pared to non-responders and ICD-only patients (Barsheshet et al.,
2011). CRT is also associated with favorable reverse remodeling
effects on the left atrium (LA), in addition to its well-established
effects on the LV, thereby possibly reducing the risk for the devel-
opment of Atrial tachycardia (AT) and AF in patients with HF
(Kies et al., 2006; Fung et al., 2008). In CRT responders, signif-
icant improvement in left atrial (LA) functional, structural and
anatomic remodeling have been shown in detailed echocardio-
graphic assessments during follow-up (Donal et al., 2009). In
addition, CRT responders have been shown to develop much
lower incidence of AF during follow up period compared to
non-responders (D’Ascia et al., 2011). In the MADIT-CRT trial,
favorable reverse remodeling of the LA with CRT-D therapy was
associated with a significant reduction in risk of subsequent AT
(Brenyo et al., 2011). Although aforementioned studies and few
other small studies mostly observational have reported decreased
atrial arrhythmic incidence in CRT patients, a post-hoc analysis of
large randomized CARE-HF study failed to show any atrial anti-
arrhythmic effect of CRT (Hoppe et al., 2006). These studies have
been evaluated in a recent meta-analysis by Hess et al. (2013)
The effects of CRT may also potentially be pro-arrhythmic.
Pacing the LV epicardially results in non-physiological direction
of activation which can lead to prolongation of action poten-
tial duration, potentially leading to prolongation of repolarization
(Medina-Ravell et al., 2003; Fish et al., 2005). In patients with dis-
eased ventricles with heterogeneous conduction, re-entry may be
facilitated by pacing close to scar border or lines of block or may
provoke ectopy leading to arrhythmia (Fish et al., 2005).
How the balance of these potential pro- and anti-arrhythmic
mechanisms lies in different groups of patients, different
etiologies of heart disease, and different conduction defects is
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unknown. Data from the present study and previous large, ran-
domized trials (Voigt et al., 2006; Barsheshet et al., 2011) would
support a net beneficial effect overall, but whether this is true for
each individual patient is also undetermined. Previous reports
of VT storm occurring acutely after CRT implantation demon-
strate this balance can be difficult to predict (Kantharia et al.,
2006; Nayak et al., 2008) and may simply reflect the lack of time
for reverse remodeling to occur with CRT in some individuals.
One can speculate that as this is only seen in a small fraction
of patients, unusual interplay of specific characteristics may be
responsible. LV structural abnormalities, local conduction delay
and repolarization abnormalities, LV lead position and pacing
site, circulating catecholamine levels as a result of hemodynamic
status, medications and ion channel function may all be culprits.
Finally, patients with indications for CRT are, by the nature of
their disease process, prone to VA and CRT may not always be
responsible for an increase in arrhythmia burden.
DIFFERENCES IN CRT AND ICD POPULATIONS
Patients with devices implanted for secondary prevention, ion
channelopathy, HCM, and congenital heart disease were excluded
to facilitate comparison between the two etiologies of heart fail-
ure most commonly leading to device implantation. Overall, the
two groups were reasonably well matched. However, there were
differences between these groups, which requires further discus-
sion. NYHA class was significantly higher in the CRT-D group.
This is not unexpected given the criteria for CRT implantation in
the UK stipulates NYHA class III-IV symptoms (ref NICE guide-
lines) (Appraisal Committee members and NICE project team,
2007), whereas heart failure symptoms need not be severe for
ICD implantation. As a consequence, one might expect more
severe underlying heart dysfunction in the CRT cohort, putting
them more at risk of arrhythmia, but this is not borne out by
the echocardiographic data from these two groups in the present
study (including LV systolic function), which showed no signifi-
cant difference in the mean EF, including the sub-group analysis.
We therefore speculate this symptomatic difference between the
groups is unlikely to influence the results of the study.
Patients in the ICD arm had a higher proportion of males
and patients with an ischemic substrate. The two cohorts in the
analysis were well matched in respect to renal function. This is
important as renal disease is a well-recognized independent risk
factor for sudden death in heart failure patients (Korantzopoulos
et al., 2009; Kreuz et al., 2010; Shamseddin and Parfrey, 2011) and
often co-exists in patients with impaired LV function. Electrolyte
abnormalities as a result of renal disease may also predispose to
VA (Whitman et al., 2012) and therefore act as a confounding
factor. The Cox regression analysis in our study identified pres-
ence of CKD as one of the independent predictors of VT/VF.
Advanced age and male-sex were the other independent pre-
dictors of sustained VAs. Additional comorbidities, including
presence of coronary disease and CKD with advancing age might
explain, age being independent predictor of sustained VA.
LIMITATIONS
This study is limited by its retrospective nature of data collection.
Some baseline characteristics (gender and drugs) were not well
matched between the two groups which may have acted as con-
founders. Moreover the sizes of the cohorts studied were small
and this is well acknowledged as one of the limitations of this
study. The use of device therapies (ATP or shocks) as a surrogate
for sustained VA is likely to be highly sensitive, but not specific.
Nominal settings for detection of VF on most devices is rela-
tively short (for example 18 out 24 intervals onMedtronic devices
or minimum 1 s of tachycardia on Boston Scientific devices)
meaning that therapy is delivered very early after the onset of
tachycardia, which may have terminated spontaneously shortly
afterwards. Thus, using this measure is likely to overestimate the
real proportion of sustained arrhythmia, but one would expect
this to be similar between the two groups as long as programmed
device detection criteria was also similar.
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